… Adenosquamous carcinoma (ASC) of the lung is a rare subtype of nonsmall-cell lung cancer
(NSCLC). To date, the efficacious targeted therapy for advanced ASC remains unclear and …

… cell carcinomas (SCC) of the lung, these mutations do occur in adenosquamous carcinomas
(… Here we present an expanded series of these cases with a focus on sensitivity to erlotinib. …

… lung SCC. The aim of this study was to evaluate the status of erlotinib treatment and EGFR
mutation in lung SCC patients. … types of lung cancer include adenocarcinoma, squamous cell …

… erlotinib, reportedly have antitumor activity in patients with nonsmall cell lung cancer and
head and neck cancer … of the EGFR TKI erlotinib in patients with esophageal cancer who had …

… squamous cell carcinoma (SCC). Although ASC has biological … stage III patients with ASC.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and …

… resistance to erlotinib in patients with lung adenocarcinoma. To … and erlotinib in patients
with acquired resistance to erlotinib, … Experimental Design: Patients with lung adenocarcinoma …

… In summary, erlotinib and cetuximab treatment was … months/PR in five of 20 patients with
non–small cell lung cancer (25%), … 6 patients with adenocarcinoma histology versus 4 patients …

… of adenocarcinoma are contraindicated in patients with squamous cell … for patients with
squamous cell carcinoma of the lung. Afatinib reduced the risk of death compared with erlotinib …

… 19, and patients with adenocarcinoma (figure … erlotinib and chemotherapy in patients
who were smokers, those with EGFR mutation type exon 21, and patients with non-adenocarcinoma…

… in heavily pretreated patients with adenocarcinoma NSCLC whose tumors had such a …
study was different from that observed in adenocarcinoma NSCLC, in which the most frequently …